Last updated on April 2019

An Study to Investigate the Safety and Efficacy of PA21 (Velphoro ) and Calcium Acetate (Phoslyra ) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia


Brief description of study

This a Phase 3, Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Study to Investigate the Safety and Efficacy of PA21 (Velphoro) and Calcium Acetate (Phoslyra) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia. The aim of this Phase 3 clinical study is to demonstrate similar efficacy of PA21 (Velphoro) in paediatric and adolescent patients with CKD, and to provide safety and dosing information for this patient population. The Phoslyra (comparator) group provides information for a descriptive comparison of PA21 against a commonly used calcium-based phosphate binder (calcium acetate).

Clinical Study Identifier: NCT02688764

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.